Skip to content. | Skip to navigation

European Coalition on Homeopathic & Anthroposophic Medicinal Products



ECHAMP’s report, The Availability of Homeopathic and Anthroposophic Medicinal Products in the EU, including data from two independent surveys by PwC, provides an objective analysis of the status and deficits concerning the availability of homeopathic and anthroposophic medicinal products in the EU. It concludes that:

This picture is of a logo which demonstrates how homeopathic medicine availability worksDemand
There is significant to high demand for homeopathic and anthroposophic medicinal products in at least two thirds of EU Member States, and this applies to countries both with and without a long-term tradition for these products.

Availability of registered/authorised homeopathic and anthroposophic medicinal products in the EU is insufficient and the demand cannot always be met. The types of products most widely available in pharmacies are those requested for self-medication.

European legislation
Implementation and enforcement of European medicines legislation for this sector has been slow and is very incomplete even twenty years after its adoption. Divergent implementation, interpretation and enforcement policy in the Member States make it extremely difficult for companies to operate across Europe.

"Regulation is the limiting factor between the strong demand for these products, made visible accross the EU, and true patient choice."

Regulatory environment
The regulatory environment, including assessment capacity and policy at national level, is not proportionate to the large range of stocks and multiple finished medicinal products produced from these stocks, which are used in homeopathic and anthroposophic therapy.  In many Member States the number of registered products poorly reflects the high numbers of homeopathic prescribers.

Availability is threatened in some Member States by the lack of a registration process, and in others by an incomplete process for the renewal of existing registrations. The regulatory burden is such that it is not sustainable to maintain registrations for the full range of medicinal products required for proper practice of these therapies.

Last updated on 07 Oct 2015